Evidence map›Paper›PMID 26626489›Full record

ArticleJournal of neuro-oncology2016

The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.

Sadhana Jackson, Nicole M Anders, Antonella Mangraviti, Teresia M Wanjiku, Eric W Sankey, Ann Liu, Henry Brem, Betty Tyler, Michelle A Rudek, Stuart A Grossman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. The effect of an adenosine AFluids and barriers of the CNS · 2018
    Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Towards updated understanding of brain metastasis.American journal of cancer research · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Purinergic Regulation of Endothelial Barrier Function.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sadhana JacksonBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA.
Nicole M AndersChemical Therapeutics and Analytical Pharmacology Core Laboratory, Johns Hopkins University, Bunting-Blaustein Cancer Research Building I, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231, USA.
Antonella MangravitiDepartment of Neurosurgery, School of Medicine, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 2M45, Baltimore, MD, 21287, USA.
Teresia M WanjikuChemical Therapeutics and Analytical Pharmacology Core Laboratory, Johns Hopkins University, Bunting-Blaustein Cancer Research Building I, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231, USA.
Eric W SankeyDepartment of Neurosurgery, School of Medicine, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 2M45, Baltimore, MD, 21287, USA.
Ann LiuDepartment of Neurosurgery, School of Medicine, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 2M45, Baltimore, MD, 21287, USA.
Henry BremDepartment of Neurosurgery, School of Medicine, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 2M45, Baltimore, MD, 21287, USA.
Betty TylerDepartment of Neurosurgery, School of Medicine, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 2M45, Baltimore, MD, 21287, USA.
Michelle A RudekChemical Therapeutics and Analytical Pharmacology Core Laboratory, Johns Hopkins University, Bunting-Blaustein Cancer Research Building I, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD, 21231, USA.
Stuart A GrossmanBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA. grossman@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR 001079NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCRR NIH HHS 1S10RR026824-01NCRR NIH HHS S10 RR026824NIGMS NIH HHS T32 GM066691NIGMS NIH HHS T32GM066691
6 · The paper itself

Abstract

The blood-brain barrier (BBB) significantly reduces the delivery of many systemically administered agents to the central nervous system. Although temozolomide is the only chemotherapy to improve survival in patients with glioblastoma, its concentration in brain is only 20 % of that in blood. Regadenoson, an FDA approved adenosine receptor agonist used for cardiac stress testing, transiently disrupts rodent BBB allowing high molecular weight dextran (70 kD) to enter the brain. This study was conducted to determine if regadenoson could facilitate entry of temozolomide into normal rodent brain. Temozolomide (50 mg/kg) was administered by oral gavage to non-tumor bearing F344 rats. Two-thirds of the animals received a single dose of intravenous regadenoson 60-90 min later. All animals were sacrificed 120 or 360 min after temozolomide administration. Brain and plasma temozolomide concentrations were determined using HPLC/MS/MS. Brain temozolomide concentrations were significantly higher at 120 min when it was given with regadenoson versus alone (8.1 ± 2.7 and 5.1 ± 3.5 µg/g, P < 0.05). A similar trend was noted in brain:plasma ratios (0.45 ± 0.08 and 0.29 ± 0.09, P < 0.05). Brain concentrations and brain:plasma ratios were not significantly different 360 min after temozolomide administration. No differences were seen in plasma temozolomide concentrations with or without regadenoson. These results suggest co-administration of regadenoson with temozolomide results in 60% higher temozolomide levels in normal brain without affecting plasma concentrations. This novel approach to increasing intracranial concentrations of systemically administered agents has potential to improve the efficacy of chemotherapy in neuro-oncologic disorders.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic Agents, AlkylatingBlood-Brain BarrierBrainDacarbazineFemalePurinesPyrazolesRatsRats, Inbred F344Tandem Mass SpectrometryTemozolomideTissue DistributionAntineoplastic Agents, AlkylatingDacarbazinePurinesPyrazolesregadenosonTemozolomideBlood–brain barrierBrain metastasesBrain tumorPharmacologyRegadenosonTemozolomide

Identifiers

PMID26626489
PMCPMC4733584
OpenAlexW2185908114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.